Evidence map›Paper›PMID 39239871›Full record

ArticleJournal of comparative effectiveness research2024

How pharma can amplify product value with implementation science.

Melvin Skip Olson, Leah L Zullig, Sabina De Geest

Abstract readEditorial
In one paragraph

Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Melvin Skip OlsonOlson Strategies GmbH, Allschwil, 4123, Switzerland.ORCID 0009-0004-6841-7336
Leah L ZulligCenter for Innovation to Accelerate Discovery & Practice Transformation (ADAPT), Durham Veterans Affairs Health Care & System, & Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC 27701, USA.ORCID 0000-0002-6638-409X
Sabina De GeestInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, 4056, Switzerland.ORCID 0000-0001-6596-7237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving blockbuster status requires more than clinical trial success. Crucial barriers often include real-world factors like patient acceptance, prescriber behavior and timely and full reimbursement. Implementation science can be used to identify such barriers, develop strategies to overcome them, as well as test their effect. Used correctly and at the right time, implementation science can amplify product value and lead to a triple win for patients, healthcare systems and pharma. Three easy steps that focus on context, strategies and outcomes, can be followed by pharma to bring implementation thinking and research into their processes. A 'what if' case study is shared to give an indication of how this might work and the impact it might have.

Indexed as

Implementation ScienceComparative Effectiveness ResearchDrug IndustryHumansadoptionhealthcare systemsimplementation scienceintegrated evidence

Identifiers

PMID39239871
PMCPMC11426286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.